Federated Hermes 13F: Cuts CNTA Stake by $12M

Federated Hermes has cut its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA), trimming 292,700 shares in its latest SEC filing. This reduction represents a 12.5% decrease, leaving the fund with 2,049,439 shares valued at approximately $83 million as of the reporting period.

What Changed in Federated Hermes's Centessa Pharmaceuticals Position

Federated Hermes reduced its holdings in Centessa Pharmaceuticals by 292,700 shares, which marks a 12.5% decrease. The fund now holds 2,049,439 shares, down from 2,342,139 shares previously. The value of this position is reported at about $83 million.

Other Institutional Activity in Centessa Pharmaceuticals

Several other institutional investors also adjusted their positions in Centessa Pharmaceuticals. Avoro Capital Advisors reduced its holdings by 3,125,100 shares, ending with 11,430,455 shares worth about $454 million, a 21.5% decrease. Adage Capital Partners trimmed its stake by 2,356,731 shares, now holding 8,925,010 shares valued at $354 million, reflecting a 20.9% decrease. In contrast, Pentwater Capital Management opened a new position with 8,170,000 shares, valued at approximately $325 million.

Centessa Pharmaceuticals Stock Snapshot

As of Wednesday, shares of Centessa Pharmaceuticals traded near $40.50. The company has a market capitalization of $6.22 billion. Its forward P/E ratio is not meaningful as it is currently not profitable, with a beta of 1.121. The stock's 52-week range is between $12.39 and $40.26, with a 50-day moving average of $39.66 and a 200-day moving average of $28.96. The company maintains a strong liquidity position with a current ratio of 9.53 and a quick ratio of 9.27, alongside a debt-to-equity ratio of 24.33.

Recent Earnings

Centessa Pharmaceuticals reported negative earnings per share (EPS) of -$1.78, with no net margin due to its unprofitable status. The company has a return on equity (ROE) of -57.38%. Investors can expect the next earnings report on August 11, 2026.

Insider Buying and Selling at Centessa Pharmaceuticals plc

CEO Mario Alberto Accardi sold 604 shares at an average price of $39.42 on May 1, 2026. Chief People Officer Karen Anderson sold 41,076 shares on March 26, 2026, as part of a planned transaction at $30.12, having previously bought the same amount at $8.01. Additionally, Chief Business Officer Gregory Weinhoff sold 23,998 shares on March 26, 2026, after purchasing them at $3.85.

Analysts Set New Price Targets

On April 20, 2026, Wells Fargo downgraded Centessa Pharmaceuticals to a 'hold' rating with a price target of $42.00. Earlier, on April 1, 2026, Leerink Partners also downgraded the stock to 'hold' with a $40.00 target. Wolfe Research initiated coverage with a 'buy' rating and a $40.00 target on February 24, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $44.17 based on six analyst opinions.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a biotechnology company focused on developing orexin-based neuroscience therapeutics. Headquartered in Altrincham, United Kingdom, the company is led by CEO Dr. Mario Alberto Accardi. It is involved in developing treatments for central disorders of hypersomnolence, including narcolepsy. Centessa also explores treatments for neurological and neurodegenerative disorders, neuropsychiatric disorders, and has an early-stage immuno-oncology program. Founded in 2020, it employs 129 people.

Bottom Line

Federated Hermes's reduction in Centessa Pharmaceuticals reflects its latest investment strategy as reported in the SEC filing. While Centessa's stock has shown volatility, its market cap and institutional interest suggest ongoing investor attention. Investors look to these filings for insights, though they represent past positions and may not reflect current holdings.